Breast cancer: distinct survival patterns with single hormone receptor-positive disease

  • Li Y & al.
  • JAMA Netw Open
  • 3 janv. 2020

  • Par Miriam Davis, PhD
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • Patients with ER/PR+ cancers have worse breast cancer-specific survival (BCSS) than patients with ER+/PR breast cancer.

Why this matters

  • It has long been known that patients with ER+/PR+ disease have better survival relative to ER/PR, but survival for patients with single hormone receptor-positive breast cancer is less examined.
  • Distinct treatment strategies for patients with single hormone receptor-positive breast cancer may be necessary.

Study design

  • A retrospective cohort of 823,399 patients with breast cancer (including 5397 men) in the Surveillance, Epidemiology, and End Results database, 1990-2015.
  • Funding: National Natural Science Foundation of China.

Key results

  • Median follow-up, 71 (range, 0-311) months.
  • Compared with patients with ER+/PR+ breast cancer:
    • Patients with ER+/PR disease had 36% worse survival (HR, 1.36; 95% CI, 1.34-1.38).
    • Patients with ER/PR+ disease had 61% worse survival (HR, 1.61; 95% CI, 1.55-1.67). 
    • Patients with ER/PR disease had 72% worse survival (HR, 1.72; 95% CI, 1.70-1.75).
  • Compared with patients with ER+/PR breast cancer:
    • Patients with ER/PR+ had 18% worse survival (HR, 1.18; 95% CI, 1.14-1.23). 
    • Patients with ER/PR had 27% worse survival (HR, 1.27; 95% CI, 1.24-1.29).

Limitations

  • Retrospective, observational design.